SEC Form 4 · accession 0001209191-16-119110
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
May 9, 2016
Accepted (ET)
May 11, 2016 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | May 9, 2016 | S | 800 | $86.69 | D | 15,950 | D | |
| Common StockF2,F4 | May 9, 2016 | S | 1,100 | $87.49 | D | 14,850 | D | |
| Common StockF3,F5 | May 9, 2016 | S | 1,100 | $88.44 | D | 13,750 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401k |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $86.69 (range $85.99 to $86.98).
- F4Open market sales reported on this line occurred at a weighted average price of $87.49 (range $86.99 to $87.94).
- F5Open market sales reported on this line occurred at a weighted average price of $88.44 (range $88.00 to $88.68).